Phase 1/2 Oxabact OC5 study, Protocol OC5-DB-01, version 3, Am 1

• Research type

  Research Study

• Full title

  A Phase 1/2, randomised, placebo-controlled, double-blind, multi-centre study to evaluate the efficacy and safety of OC5 to reduce urinary oxalate in subjects with primary hyperoxaluria

• IRAS ID

  130638

• Contact name

  Sally Hulton

• Contact email

  sally.hulton@bch.nhs.uk

• Sponsor organisation

  OxThera AB

• Eudract number

  2012-005606-22

• REC name

  South West - Central Bristol Research Ethics Committee

• REC reference

  13/SW/0171

• Date of REC Opinion

  24 Jul 2013

• REC opinion

  Further Information Favourable Opinion